On September 17, 2025, Oruka Therapeutics, Inc. announced a private placement of 10,933,405 shares at $15.00 each, totaling approximately $180 million, along with 1,066,666 pre-funded warrants. The transaction closed on September 19, 2025, significantly increasing the total shares outstanding to about 67.1 million post-conversion of preferred stock.